

Sartorius and Repligen launch integrated system for upstream process intensification

18 August 2023 | News

Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation

German firm Sartorius and US-based Repligen Corporation have announced the launch of an integrated bioreactor system that incorporates Repligen XCell ATF upstream intensification technology into Sartorius' Biostat STR bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.

The Biostat STR now contains a fully compatible embedded XCell ATF hardware and software module offering predefined advanced control recipes with integrated Process Analytical Technology (PAT). This system gives users a streamlined way to control cell growth and improve cell retention in perfusion processes without using a separate cell retention control tower.

In addition, customers can better utilise facility space with a reduced equipment footprint from the incorporation of the XCell Controller hardware and software in the Biobrain automation platform, creating a single point of control for 50 L – 2000 L upstream intensification processes. The single, integrated controller provides easy integration into Supervisory Control and Data Acquisition (SCADA) and Distributed Control Systems (DCS).

This new integrated product offering builds on Sartorius and Repligen Corporation's aligned missions to enable the development of new and better therapies and more affordable medicine through expertise and collaboration.